Fibroblast Growth Factor Receptor 4 - Pipeline Review, H2 2020
Fibroblast Growth Factor Receptor 4 - Pipeline Review, H2 2020
SUMMARY
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades.
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 6, 4, 2, 1, 3 and 1 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Metabolic Disorders, Central Nervous System and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Lung Adenocarcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Ovarian Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Type 2 Diabetes, Adenoid Cystic Carcinoma (ACC), Bladder Cancer, Esophageal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Liver Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Alcoholic Steatohepatitis (NASH), Obesity, Prostate Cancer, Squamous Non-Small Cell Lung Cancer, Thyroid Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Achondroplasia, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Colorectal Cancer, Constipation, Endometrial Cancer, Epithelial Ovarian Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Tract Cancer, Head And Neck Cancer, High-Grade Glioma, Hypopharyngeal Cancer, Laryngeal Cancer, Liver Cirrhosis, Liver Fibrosis, Lymphoma, Melanoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Nasopharyngeal Cancer, Non-Small Cell Lung Cancer, Oral Cavity (Mouth) Cancer, Oral Mucositis, Oropharyngeal Cancer, Osteosarcoma, Paranasal Sinus And Nasal Cavity Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, Primitive Neuroectodermal Tumor (PNET), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rhabdomyosarcoma, Salivary Gland Cancer, Small-Cell Lung Cancer, Spinal Cord Injury, Squamous Cell Carcinoma, Thymic Carcinoma and Triple-Negative Breast Cancer (TNBC).
The latest report Fibroblast Growth Factor Receptor 4 - Pipeline Review, H2 2020, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades.
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 6, 4, 2, 1, 3 and 1 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Metabolic Disorders, Central Nervous System and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Lung Adenocarcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Ovarian Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Type 2 Diabetes, Adenoid Cystic Carcinoma (ACC), Bladder Cancer, Esophageal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Liver Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Alcoholic Steatohepatitis (NASH), Obesity, Prostate Cancer, Squamous Non-Small Cell Lung Cancer, Thyroid Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Achondroplasia, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Colorectal Cancer, Constipation, Endometrial Cancer, Epithelial Ovarian Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Tract Cancer, Head And Neck Cancer, High-Grade Glioma, Hypopharyngeal Cancer, Laryngeal Cancer, Liver Cirrhosis, Liver Fibrosis, Lymphoma, Melanoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Nasopharyngeal Cancer, Non-Small Cell Lung Cancer, Oral Cavity (Mouth) Cancer, Oral Mucositis, Oropharyngeal Cancer, Osteosarcoma, Paranasal Sinus And Nasal Cavity Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, Primitive Neuroectodermal Tumor (PNET), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rhabdomyosarcoma, Salivary Gland Cancer, Small-Cell Lung Cancer, Spinal Cord Injury, Squamous Cell Carcinoma, Thymic Carcinoma and Triple-Negative Breast Cancer (TNBC).
The latest report Fibroblast Growth Factor Receptor 4 - Pipeline Review, H2 2020, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
- The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones
Appendix
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1)
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Abbisko Therapeutics Co Ltd, H2 2020
Pipeline by Akero Therapeutics Inc, H2 2020
Pipeline by Bayer AG, H2 2020
Pipeline by Betta Pharmaceuticals Co Ltd, H2 2020
Dormant Products, H2 2020
Discontinued Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1)
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Abbisko Therapeutics Co Ltd, H2 2020
Pipeline by Akero Therapeutics Inc, H2 2020
Pipeline by Bayer AG, H2 2020
Pipeline by Betta Pharmaceuticals Co Ltd, H2 2020
Dormant Products, H2 2020
Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Abbisko Therapeutics Co Ltd
Akero Therapeutics Inc
Bayer AG
Betta Pharmaceuticals Co Ltd
BioArdis LLC
Blueprint Medicines Corp
Eddingpharm Inc
Eisai Co Ltd
Eli Lilly and Co
EUSOL Biotech Co Ltd
Everest Medicines Ltd
Genosco Inc
H3 Biomedicine Inc
ImmunoForge Co Ltd
Incyte Corp
InnoCare Pharma Ltd
Johnson & Johnson
Merck & Co Inc
NGM Biopharmaceuticals Inc
QED Therapeutics Inc
Vichem Chemie Research Ltd
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Abbisko Therapeutics Co Ltd
Akero Therapeutics Inc
Bayer AG
Betta Pharmaceuticals Co Ltd
BioArdis LLC
Blueprint Medicines Corp
Eddingpharm Inc
Eisai Co Ltd
Eli Lilly and Co
EUSOL Biotech Co Ltd
Everest Medicines Ltd
Genosco Inc
H3 Biomedicine Inc
ImmunoForge Co Ltd
Incyte Corp
InnoCare Pharma Ltd
Johnson & Johnson
Merck & Co Inc
NGM Biopharmaceuticals Inc
QED Therapeutics Inc
Vichem Chemie Research Ltd
